A biotech incubated by RA Capital has secured a $57.5 million Series B to begin a mid-stage trial for its cardio drug this ...

Led by new investor Deep Track Capital, with participation from AN Ventures, Catalio Capital Management, Cytokinetics, Inc. and existing investors RA Capital Management and SV Health Investors – – ...

Heart failure with preserved ejection fraction (HFpEF) is a disease in which the left ventricle (LV) of the heart shows impaired relaxation during cardiac diastole, often accompanied by structural and ...

Needham analyst Serge Belanger maintained a Buy rating on Cytokinetics ( CYTK – Research Report) today and set a price target of $72.00. The company’s shares closed yesterday at $35.99. Filter, ...

California Public Employees Retirement System trimmed its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – ...

Franklin Resources Inc. boosted its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 1.7% in the fourth quarter, HoldingsChannel reports. The firm owned 545,813 shares of ...